Preclinical design of less immunogenic biologics: Tregitopes and Tolerance (144.28)
Janet E. Buhlmann(Bristol-Myers Squibb (United States)), Anne S. De Groot(Providence College), Francesca D’Addio(University of Milan), Mohamed H. Sayegh(American University of Beirut), Nader Najafian(Harvard University), Achsah Keegan(University of Maryland, Baltimore), Lesllie De Groot(University of Rhode Island), Katherine Hui(Children's Hospital of Philadelphia), Daniel J. Hui(Children's Hospital of Philadelphia), Federico Mingozzi(Spark Therapeutics (United States)), David A. Scott(Sanford Burnham Prebys Medical Discovery Institute)
Cited by 1
Related Papers
DNA targeting specificity of RNA-guided Cas9 nucleases
|Nature Biotechnology|2013|5k
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
|Nature Medicine|2007|2.2k
IMMUNE REGULATION BY CD40 AND ITS LIGAND GP39
|Annual Review of Immunology|1996|640
Immunomodulation by Mesenchymal Stem Cells
|Diabetes|2008|470
EFFECTS OF EXPLOSIVE BRAIN DEATH ON CYTOKINE ACTIVATION OF PERIPHERAL ORGANS IN THE RAT1
|Transplantation|1998|404